These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 26679967)

  • 1. A Real-World Observational Study of Time to Treatment Intensification Among Elderly Patients with Inadequately Controlled Type 2 Diabetes Mellitus.
    Ajmera M; Raval A; Zhou S; Wei W; Bhattacharya R; Pan C; Sambamoorthi U
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1184-93. PubMed ID: 26679967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of Treatment Intensification on A1c in Patients with Suboptimally Controlled Type 2 Diabetes After 2 Oral Antidiabetic Agents.
    Kim K; Unni S; McAdam-Marx C; Thomas SM; Sterling KL; Olsen CJ; Johnstone B; Mitchell M; Brixner D
    J Manag Care Spec Pharm; 2019 Mar; 25(3):314-322. PubMed ID: 30816811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population.
    Grabner M; Peng X; Geremakis C; Bae J
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1204-12. PubMed ID: 26679969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Slow Titration and Delayed Intensification of Basal Insulin Among Patients with Type 2 Diabetes.
    Mocarski M; Yeaw J; Divino V; DeKoven M; Guerrero G; Langer J; Thorsted BL
    J Manag Care Spec Pharm; 2018 Apr; 24(4):390-400. PubMed ID: 29406841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors associated with Prolonged Inaction in the hypoglycaemic treatment in people with non-insulin dependent Type 2 Diabetes and elevated glycated haemoglobin: A registry-based cohort study.
    Goderis G; Vaes B; Van den Akker M; Elli S; Mathieu C; Buntinx F; Henrard S
    Prim Care Diabetes; 2017 Oct; 11(5):482-489. PubMed ID: 28648964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health Outcomes Associated with Initiation of Basal Insulin After 1, 2, or ≥ 3 Oral Antidiabetes Drug(s) Among Managed Care Patients with Type 2 Diabetes.
    Levin PA; Zhou S; Gill J; Wei W
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1172-81. PubMed ID: 26679966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and tolerability of second-line treatment with vildagliptin versus other oral drugs for type 2 diabetes in a real-world setting in the Middle East: results from the EDGE study.
    Saab C; Al-Saber FA; Haddad J; Jallo MK; Steitieh H; Bader G; Ibrahim M
    Vasc Health Risk Manag; 2015; 11():149-55. PubMed ID: 25750538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment intensification for patients with type 2 diabetes and poor glycaemic control.
    Fu AZ; Sheehan JJ
    Diabetes Obes Metab; 2016 Sep; 18(9):892-8. PubMed ID: 27160505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes and treatment patterns of adding a third agent to 2 OADs in patients with type 2 diabetes.
    Levin PA; Wei W; Zhou S; Xie L; Baser O
    J Manag Care Spec Pharm; 2014 May; 20(5):501-12. PubMed ID: 24761822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
    Wang JS; Lin SD; Lee WJ; Su SL; Lee IT; Tu ST; Tseng YH; Lin SY; Sheu WH
    Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical course and outcomes of type-2 diabetic patients after treatment intensification for insufficient glycaemic control - results of the 2 year prospective DiaRegis follow-up.
    Bramlage P; Gitt AK; Schneider S; Deeg E; Tschöpe D;
    BMC Cardiovasc Disord; 2014 Nov; 14():162. PubMed ID: 25410473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Third-Line Antidiabetic Therapy Intensification Patterns and Glycaemic Control in Patients with Type 2 Diabetes in the USA: A Real-World Study.
    Koye DN; Montvida O; Paul SK
    Drugs; 2020 Apr; 80(5):477-487. PubMed ID: 32141024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes.
    Paul SK; Klein K; Thorsted BL; Wolden ML; Khunti K
    Cardiovasc Diabetol; 2015 Aug; 14():100. PubMed ID: 26249018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and tolerability of treatment intensification to basal-bolus therapy in patients with type 2 diabetes on previous basal insulin-supported oral therapy with insulin glargine or supplementary insulin therapy with insulin glulisine: the PARTNER observational study.
    Pfohl M; Siegmund T; Pscherer S; Pegelow K; Seufert J
    Vasc Health Risk Manag; 2015; 11():569-78. PubMed ID: 26604774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Individualised treatment targets in patients with type-2 diabetes and hypertension.
    Schmieder RE; Tschöpe D; Koch C; Ouarrak T; Gitt AK;
    Cardiovasc Diabetol; 2018 Jan; 17(1):18. PubMed ID: 29357854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between intensive glycemic control and mortality in elderly diabetic patients in the primary care: A retrospective cohort study.
    Ying DG; Ko SH; Li YC; Chen CX
    Prim Care Diabetes; 2020 Oct; 14(5):476-481. PubMed ID: 32291184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time to Treatment Intensification After Monotherapy Failure and Its Association With Subsequent Glycemic Control Among 93,515 Patients With Type 2 Diabetes.
    Desai U; Kirson NY; Kim J; Khunti K; King S; Trieschman E; Hellstern M; Hunt PR; Mukherjee J
    Diabetes Care; 2018 Oct; 41(10):2096-2104. PubMed ID: 30131396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors Associated with Diabetes-Related Clinical Inertia in a Managed Care Population and Its Effect on Hemoglobin A1c Goal Attainment: A Claims-Based Analysis.
    Ruiz-Negrón N; Wander C; McAdam-Marx C; Pesa J; Bailey RA; Bellows BK
    J Manag Care Spec Pharm; 2019 Mar; 25(3):304-313. PubMed ID: 30816810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensification of antihyperglycemic therapy among patients with incident diabetes: a Surveillance Prevention and Management of Diabetes Mellitus (SUPREME-DM) study.
    Raebel MA; Ellis JL; Schroeder EB; Xu S; O'Connor PJ; Segal JB; Butler MG; Schmittdiel JA; Kirchner HL; Goodrich GK; Lawrence JM; Nichols GA; Newton KM; Pathak RD; Steiner JF
    Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):699-710. PubMed ID: 24639086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of a Pharmacist-Managed Diabetes Program in a Primary Care Setting Within an Integrated Health Care System.
    Benedict AW; Spence MM; Sie JL; Chin HA; Ngo CD; Salmingo JF; Vidaurreta AT; Rashid N
    J Manag Care Spec Pharm; 2018 Feb; 24(2):114-122. PubMed ID: 29384029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.